3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
31
Carcinoma, Hepatocellular
30
Neoplasms
19
Carcinoma, Renal Cell
16
Melanoma
10
Carcinoma, Non-Small-Cell Lung
10
Thyroid Neoplasms
9
Endometrial Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
6
Colorectal Neoplasms
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Liver Neoplasms
4
Carcinoma, Transitional Cell
4
Uterine Cervical Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Lymphoma
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Carcinoma
3
Biliary Tract Neoplasms
3
Stomach Neoplasms
2
Solid Tumors
2
Osteosarcoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Glioma
2
Diabetes Mellitus, Insulin-Dependent, 12
2
Interventions
enzalutamide
5
abiraterone
3
Prednisone
3
Docetaxel
3
Abiraterone Acetate
3
relugolix
1
pembrolizumab
1
onvansertib
1
olaparib
1
lenvatinib
1
inavolisib
1
belzutifan
1
apalutamide
1
abemaciclib
1
Prednisolone
1
PF06821497
1
Methylprednisolone
1
Lutetium-177
1
Lutetium
1
Gonadotropin-Releasing Hormone
1
Etoposide
1
Dexamethasone
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metastatic Castration-Resistant Prostate Cancer
×
lenvatinib
×
Clear all
NCT02861573
2026-02-17
KEYNOTE-365
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
1,200 enrolled